Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
|Videos|December 22, 2022
Combination of NAI and BCG found safe, effective in treatment of NMIBC
Author(s)Urology Times staff
“The combination of NAI plus BCG was safe, it was effective, and it serves as a feasible and viable alternative to other agents in this disease space,” says Karim Chamie, MD.
Advertisement
In this interview, Karim Chamie, MD, shares interim findings from the ongoing study, “IL-15 superagonist NAI in BCG-unresponsive non–muscle-invasive bladder cancer." Chamie is an associate professor of urology at the University of California, Los Angeles.
Advertisement
Related to this article
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
The PDUFA target action date is in the fourth quarter of 2026.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
2026 AUA/SUO NMIBC guideline: Key updates for clinical practice
3
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
4
AUA South Central Section Meeting: Mark D. Tyson, II, MD, MPH, recaps data in NMIBC
5